Mat***luk

Chief Business Officer

Bildung

Carnegie Mellon University - Tepper School of Business

Carnegie Mellon University - Tepper School of Business (2006 - 2008)

  • Degree: MBA
  • Field of Study: Entrepreneurship, Finance, Marketing, Strategy
  • Description: William G. McGowan Scholar, James R. Swartz Entrepreneurial Fellow, Tepper School of Business Merit Scholarship Recipient, Walter Rittman Endowed Scholar

University of Pittsburgh School of Medicine (Unknown - 2006)

  • Degree: PhD
  • Field of Study: Cell Biology, Biochemistry
  • Description: Dissertation: Protein Interaction Domains in Clathrin-Mediated Endocytosis.

University of Notre Dame (Unknown - Present)

  • Degree: BS
  • Field of Study: Biochemistry
  • Description:

Fähigkeiten:

Business Development, Strategy, Biotechnology, Product Management

Berufserfahrung:

Chief Business Officer at AIRNA

  • Location:
  • Duration: 2025-01 to Present
  • Description:

Director, Board of Directors at OUROTECH, INC. (D.B.A. PEAR BIO)

  • Location: London, United Kingdom
  • Duration: 2024-07 to Present
  • Description:

Director, Board of Directors at Predictive Oncology

  • Location:
  • Duration: 2022-11 to Present
  • Description:

Advisory Board Member at PathAI

  • Location: Boston, Massachusetts, United States
  • Duration: 2020-03 to Present
  • Description:

EVP, Chief Business Officer & Boston Site Head at Gritstone bio

  • Location: Cambridge, MA
  • Duration: 2015-11 to 2025-01
  • Description: Executive Vice President and Chief Business Officer, 1/2015 – Present Head of Legal, 9/2022 – Present Boston Site Head (Previously Cambridge, MA), 7/2021 – Present Led several pivotal deals w/ Government and non-government partners • BARDA project and submission of Broad Agency Announcement application including Technical and Cost Volumes and negotiation of the contract to conduct a comparative 10,000 subject Phase 2b clinical trial evaluating a next-generation vaccine candidate for COVID-19 with funding valued up to $433M (Sep’23) • Collaboration, Option and License agreement with Gilead Sciences to research and develop an HIV cure (Jan’21), utilizing Gritstone technology for Gilead’s development and commercialization. Total deal value of $785M with $60M upfront • Research collaboration and license agreement with bluebird bio (now 2seventy bio) whereby Gritstone provides tumor-specific targets and TCRs for cell therapy (Aug’18). Total deal value of $1.2B with $20M upfront cash and $20M in equity ($10M in Series C and $10M in IPO) • Grant agreements with Bill & Melinda Gates Foundation funding for an optimal immunogen for HPV eradication ($3.2M) and for a next-generation SARS-CoV-2 vaccine ($575K) • Funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a second-generation samRNA SARS-CoV-2 vaccine in South Africa. Funding up to $25.6M for a multi-arm Phase 1 study, preclinical studies, and scale-up, and formulation development
KI-Lebenslaufanalyse

Kandidaten-Intelligenzbericht

KI-gestützte Analyse aus der Perspektive eines US-Einstellungsdirektors — Bewertung von Karrierekontinuität, Wachstumstrajektorie und Rollenpassung.

Karrierekontinuität und Risikobewertung

Employment GapLow

No gaps in employment are evident; the candidate has maintained continuous work in senior biotech leadership and advisory roles since 2015.

Industry ConsistencyLow

Career across biotechnology, biopharma, and life sciences partnerships is highly consistent with educational background and skill set.

Tenure StabilityLow

A long tenure at Gritstone (2015–2025) demonstrates stability; subsequent transitions to AIRNA and ongoing governance roles are typical for senior biotech executives and not indicative of instability.

Education-Career MatchLow

CMU Tepper School of Business credentials align with C-suite BD/strategy roles in biotech, supporting a strong education-career fit.

Karrierewachstumskurve

EVP, Chief Business Officer & Boston Site Head Entry
Gritstone bio
2015-11 to 2025-01
Boston Site Head ↑ Befördert
Gritstone bio
2021-07 to 2025-01
Head of Legal ↑ Befördert
Gritstone bio
2022-09 to 2025-01
Advisory Board Member Lateral
PathAI
2020-03 to Present
Director, Board of Directors Lateral
Predictive Oncology
2022-11 to Present
Director, Board of Directors Lateral
OUROTECH (D.B.A. PEAR BIO)
2024-07 to Present
Chief Business Officer Entry
AIRNA
2025-01 to Present
Bewertung:Matthew demonstrates a clear upward trajectory with deep biopharma business development, strategic partnerships, and board governance experience. The progression to AIRNA as CBO, along with multiple board/advisory roles, positions him for CEO or Chief Strategy/Commercial leadership roles at a growth-stage or mature biotech organization.

Bestpassende Rollen (Top 5)

1

Chief Executive Officer (CEO)97% Passung

Proven P&L leadership, extensive deal-making at scale (e.g., HIV cure collaboration, COVID-19 vaccines), and multi-board governance experience, all of which align with steering a biotech company toward growth and commercialization milestones.

2

Chief Commercial Officer (CCO) / Chief Business Officer (CBO)92% Passung

Direct alignment with a decade of business development and strategic partnerships, including major industry deals and government collaborations; strong network across pharma and biotech partners.

3

Chief Strategy Officer (CSO) / Head of Corporate Development90% Passung

Expertise in formulating growth strategies and negotiating high-value collaborations; well-suited to align product portfolios with market opportunities and corporate strategy.

4

Non-Executive Director (Board Director) – Life Sciences85% Passung

Extensive board governance experience across multiple biotech entities; brings risk oversight, strategic judgment, and stakeholder management to boards.

5

Senior Vice President, Corporate Development82% Passung

Deep experience in licensing, collaborations, and strategic partnerships; ideal for driving growth initiatives within a larger biopharma/biotech organization.

Erleben Sie AI Recruiter

Kostenlos starten. Lassen Sie Ihre Konkurrenten nicht den KI-Vorteil zuerst ergattern.

Schließen Sie sich über 10.000 Unternehmen an, die KI-gestützte Recruiting-Lösungen nutzen, um Ihren Einstellungsprozess zu automatisieren und 80% Zeitkosten zu sparen.

33% Rabatt, nur noch 48 Stunden!
Kostenlos AI testen

24/7 automatisierter Betrieb

KI-gestützte Kandidatenauswahl

Recruiting ohne geografische oder zeitliche Einschränkungen

Personalisierte intelligente Kommunikation

Automatisierte Bewertung des Kandidatenengagements

Ahmt Ihren Recruiting-Stil intelligent nach

4-monatige Geld-zurück-Garantie

Gewährleistet LinkedIn-Kontosicherheit